Global Human Vaccine Market 2016-2020

Description: About Human Vaccine

According to the Centers for Disease Control and Prevention (CDC), a vaccine is a product that stimulates a person’s immune system to produce immunity to a specific disease, protecting the person from that disease. Vaccines are usually administered through needle injections, but can also be administered by mouth or sprayed into the nose.

Human vaccines are of two types: preventable human vaccines and therapeutic human vaccines. Preventable human vaccines are used both for adults and children. Pediatric human vaccines are used to immunize children against various infectious diseases such as diphtheria, influenza, hepatitis, pneumococcal diseases, and meningococcal diseases.

The analysts forecast the global human vaccines market to grow at a CAGR of 11.69% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global human vaccines market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of preventable and therapeutic human vaccines.

The market is divided into the following segments based on geography:
- Americas
- APAC
- Europe

The report, Global Human Vaccine Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- GlaxoSmithKline
- Merck
- Pfizer
- Sanofi

Other prominent vendors
- Abbott
- AstraZeneca
- Bavarian Nordic
- Baxter
- Bharat Biotech
- Bharat Immunologicals and Biologicals
- bioCSL
- Bio Med
- Crucell
- Dynavax Technologies
- Indian Immunologicals
- Janssen Pharmaceuticals
- Kaketsuken
- LG Life Sciences
- Mitsubishi Tanabe Pharma
- Lupin
- Nuron
- Novartis
- Protein Sciences Corporation
- Panacea Biotec
Roche
- Serum Institute of India
- Shenzhen Kangtai Biological Products
- Sinovac Biotech
- S K Chemicals
- Takeda Pharmaceutical
- Valeant Pharmaceuticals
- Zydus Cadila

Market drivers
- Growing awareness about vaccination and immunization programs
- For a full, detailed list, view the full report

Market challenges
- Inadequate vaccination coverage
- For a full, detailed list, view the full report

Market trends
- Increase in strategic alliance and M&A
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
- Subunit vaccines

PART 09: Market segmentation by composition
- Mono vaccine
- Combination vaccines

PART 10: Market segmentation by route of administration
- Oral vaccines
- Intramuscular vaccines
- Intranasal vaccines
- Intradermal vaccines

PART 11: Market segmentation by type of human vaccine

PART 12: Global therapeutics human vaccines market
- Market overview
- Market size and forecast

PART 13: Global preventable human vaccines market
- Market overview
- Market size and forecast

PART 14: Global pediatric preventable human vaccines market
- Market size and forecast

PART 15: Global adult preventable human vaccines market
- Market size and forecast

PART 16: Geographical segmentation
- Human vaccines market in the Americas
- Market size and forecast
- Human vaccines market in EMEA
- Market size and forecast
- Human vaccines market in APAC
- Market size and forecast

PART 17: Market drivers
- Growing awareness about vaccination and immunization programs
- Inclusion in national immunization schedule
- High demand for pediatric vaccines
- Increase in prevalence of infectious diseases

PART 18: Impact of drivers

PART 19: Market challenges
- Inadequate vaccination coverage
- Vaccine storage and handling issues
- High risk associated with vaccine development
- Stringent regulatory process
- Misperception about vaccines
- Adverse side effects of vaccines

PART 20: Impact of drivers and challenges

PART 21: Market trends
- Increase in strategic alliance and M&A
- Entry of novel vaccines
- Increase in investment
- Focus on emerging markets
- Emergence of resistant strains
- Public-private initiatives

PART 22: Vendor landscape
- Competitive scenario

PART 23: Key vendor analysis
- GSK
- Sanofi
- Merck
- Pfizer
- Other prominent vendors

PART 24: Appendix
- List of abbreviations

PART 25: About the Author

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Requirements for BLA submission in the US
Exhibit 03: Developmental steps required to reach the vaccine licensing stage
Exhibit 04: Vaccine development process over a period of up to 15 years at a cost of up to $1 billion
Exhibit 05: Regulatory testing of licensed vaccines
Exhibit 06: Pediatric/VFC vaccine price list
Exhibit 07: Pediatric influenza vaccine price list
Exhibit 08: Adult vaccine price list
Exhibit 09: Adult influenza vaccine price list
Exhibit 10: GlaxoSmithKline: Vaccine pipeline
Exhibit 11: Novartis: Vaccine pipeline
Exhibit 12: Merck: vaccine pipeline
Exhibit 13: Pfizer: vaccine pipeline
Exhibit 14: Sanofi: vaccine pipeline
Exhibit 15: TuBerculosis Vaccine Initiative (TBVI): vaccine pipeline
Exhibit 16: Some pipeline compounds under development in 2015
Exhibit 17: Top 10 pharmaceutical companies based on global vaccine revenues in 2014 ($ millions)
Exhibit 18: Global human vaccines market 2015-2020 ($ billions)
Exhibit 19: SWOT analysis
Exhibit 20: Five forces analysis
Exhibit 21: Global human vaccines market segmentation by type of vaccine
Exhibit 22: Examples of vaccines by type
Exhibit 23: Global human vaccines market segmentation by composition
Exhibit 24: Global human vaccines market segmentation by route of administration
Exhibit 25: Route of administration for different vaccines
Exhibit 26: Global human vaccines market types
Exhibit 27: Global preventable and therapeutic human vaccines market share 2015
Exhibit 28: Global therapeutic human vaccines market 2015-2020 ($ billions)
Exhibit 29: Global preventable human vaccines market 2015-2020 ($ billions)
Exhibit 30: Global preventable human vaccines market categories
Exhibit 31: Global pediatric and adult preventable human vaccines market share 2015
Exhibit 32: Global pediatric preventable human vaccines market segmentation 2015
Exhibit 33: Global pediatric preventable human vaccines market 2015-2020 ($ billions)
Exhibit 34: Global adult preventable human vaccines market share 2015
Exhibit 35: Global adult preventable human vaccines market 2015-2020 ($ billions)
Exhibit 36: Global human vaccines market by geography 2015
Exhibit 37: Global human vaccines market by region 2015-2020 ($ billions)
Exhibit 38: Human vaccines market in the Americas 2015-2020 ($ billions)
Exhibit 39: Human vaccines market in EMEA 2015-2020 ($ billions)
Exhibit 40: Human vaccines market in APAC 2015-2020 ($ billions)
Exhibit 41: Impact of drivers
Exhibit 42: Global immunization coverage 2014
Exhibit 43: A typical cold chain process
Exhibit 44: Adverse effects associated with some preventable human vaccines
Exhibit 45: Impact of drivers and challenges
Exhibit 46: M&A in the vaccine industry
Exhibit 47: Overview of major vaccine-related acquisitions (2005-2012)
Exhibit 48: Market share analysis of top pharma vaccine companies, 2014
Exhibit 49: GSK: Business segmentation by revenue 2014
Exhibit 50: GSK: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 51: GSK: Geographical segmentation by revenue 2014
Exhibit 52: GSK: YoY revenue growth of Infanrix/Pediarix 2012-2014 ($ millions)
Exhibit 53: GSK: YoY revenue growth of Hepatitis vaccine 2012-2014 ($ millions)
Exhibit 54: GSK: YoY revenue growth of Synflorix 2012-2014 ($ millions)
Exhibit 55: GSK: YoY revenue growth of Rotarix 2012-2014 ($ millions)
Exhibit 56: GSK: YoY revenue growth of Boostrix 2012-2014 ($ millions)
Exhibit 57: GSK: Meningitis vaccine revenue 2013 and 2014 ($ millions)
Exhibit 58: GSK: Travel and paediatrics vaccine revenue 2013 and 2014 ($ millions)
Exhibit 59: Key takeaways
Exhibit 60: Sanofi: Business segmentation by revenue 2014
Exhibit 61: Sanofi: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 62: Sanofi: Geographical segmentation by revenue 2014
Exhibit 63: Sanofi: YoY revenue growth of Polio/pertussis/Hib vaccines ($ millions)
Exhibit 64: Sanofi: YoY revenue growth of influenza vaccines 2012-2014 ($ millions)
Exhibit 65: Sanofi: YoY revenue growth of meningitis/pneumonia vaccine 2012-2014 ($ millions)
Exhibit 66: Sanofi: YoY revenue growth of adult booster vaccine 2012-2014 ($ millions)
Exhibit 67: Sanofi: YoY revenue growth of travel and other endemic vaccines 2012-2014 ($ millions)
Exhibit 68: Key takeaways
Exhibit 69: Merck: Business segmentation by revenue 2014
Exhibit 70: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 71: Merck: Geographical segmentation by revenue 2014
Exhibit 72: Merck: YoY revenue growth of Gardasil 2012-2014 ($ millions)
Exhibit 73: Merck: YoY revenue growth of ProQuad/MMR II/Varivax 2012-2014 ($ millions)
Exhibit 74: Merck: YoY revenue growth of Zostavax 2012-2014 ($ millions)
Exhibit 75: Merck: YoY revenue growth of Pneumovax 23 2012-2014 ($ millions)
Exhibit 76: Merck: YoY revenue growth of RotaTeq 2012-2014 ($ millions)
Exhibit 77: Key takeaways
Exhibit 78: Pfizer: Business segmentation by revenue 2014
Exhibit 79: Pfizer: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 80: Pfizer: Geographical segmentation by revenue 2014
Exhibit 81: Pfizer: YoY revenue growth of Prevnar family 2012-2014 ($ millions)
Exhibit 82: Key takeaways

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/3608929/](http://www.researchandmarkets.com/reports/3608929/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Human Vaccine Market 2016-2020
Web Address: http://www.researchandmarkets.com/reports/3608929/
Office Code: SCBR3S28

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 3000</td>
</tr>
<tr>
<td>Electronic (PDF) - 1 - 5 Users</td>
<td></td>
<td>USD 3500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4500</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 10000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title:  Mr [ ]  Mrs [ ]  Dr [ ]  Miss [ ]  Ms [ ]  Prof [ ]
First Name: ___________________________  Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World